Literature DB >> 15904467

Overexpression of MUC13 is associated with intestinal-type gastric cancer.

Takahiro Shimamura1, Hirotaka Ito, Junji Shibahara, Akira Watanabe, Yoshitaka Hippo, Hirokazu Taniguchi, Yongxin Chen, Takeshi Kashima, Toshihiko Ohtomo, Fumihiko Tanioka, Hiroko Iwanari, Tatsuhiko Kodama, Teruhisa Kazui, Haruhiko Sugimura, Masashi Fukayama, Hiroyuki Aburatani.   

Abstract

Mucins are secreted or transmembrane glycoproteins that are expressed mainly in the digestive tract. This family of proteins has been the focus of much gastric cancer research as some transmembrane mucins are implicated in tumorigenesis and make attractive targets for cancer diagnosis and therapeutics. Mucins have also been utilized to classify gastric cancer by differentiating between gastric and intestinal phenotypes. Here we show that transmembrane mucin MUC13 is upregulated in gastric cancer. By quantitative real-time reverse transcription-polymerase chain reaction and immunoblot analysis, overexpression of MUC13 was verified in more than half of the samples examined. In immunohistochemical analysis, MUC13 staining was observed in 74 of 114 cases of gastric cancer (64.9%), predominantly in intestinal type (P < 0.001), and in 9 of 10 cases of intestinal metaplasia, precancerous lesions of intestinal-type gastric cancer, but not observed in normal gastric mucosa. Moreover, MUC13 staining patterns characteristic of histological type were identified: staining was on the apical side of tubular glands in intestinal type and on the cytoplasm in diffuse type. These results suggest that MUC13 is a good differentiation marker for gastrointestinal mucosa and that it may have a causal role that correlates with two distinct gastric tumorigenesis pathways.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15904467     DOI: 10.1111/j.1349-7006.2005.00043.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  29 in total

Review 1.  Genetically engineered mucin mouse models for inflammation and cancer.

Authors:  Suhasini Joshi; Sushil Kumar; Sangeeta Bafna; Satyanarayana Rachagani; Kay-Uwe Wagner; Maneesh Jain; Surinder K Batra
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

2.  Anti-tumor efficacy evaluation of a novel monoclonal antibody targeting neutral amino acid transporter ASCT2 using patient-derived xenograft mouse models of gastric cancer.

Authors:  Noriyuki Kasai; Aya Sasakawa; Kenta Hosomi; Tze Wei Poh; Bernadette Lynn Chua; Wei Peng Yong; Jimmy So; Shing Leng Chan; Richie Soong; Koji Kono; Toshihiko Ishii; Kazuya Yamano
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

Review 3.  Resistance to ETEC F4/F18-mediated piglet diarrhoea: opening the gene black box.

Authors:  Rebeka Sinha; Nihar Ranjan Sahoo; Kush Shrivastava; Pushpendra Kumar; Salauddin Qureshi; Ujjwal Kumar De; Amit Kumar; Gandham Venkata Papa Pydi Siva Ravi Kumar; Bharat Bhushan
Journal:  Trop Anim Health Prod       Date:  2019-05-24       Impact factor: 1.559

4.  Gastric de novo Muc13 expression and spasmolytic polypeptide-expressing metaplasia during Helicobacter heilmannii infection.

Authors:  Cheng Liu; Annemieke Smet; Caroline Blaecher; Bram Flahou; Richard Ducatelle; Sara Linden; Freddy Haesebrouck
Journal:  Infect Immun       Date:  2014-05-27       Impact factor: 3.441

5.  Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer.

Authors:  Hyuk-Joon Lee; Ki Taek Nam; Heae Surng Park; Min A Kim; Bonnie J Lafleur; Hiroyuki Aburatani; Han-Kwang Yang; Woo Ho Kim; James R Goldenring
Journal:  Gastroenterology       Date:  2010-04-13       Impact factor: 22.682

6.  Dose-dependent benefits of quercetin on tumorigenesis in the C3(1)/SV40Tag transgenic mouse model of breast cancer.

Authors:  Jl Steiner; Jm Davis; Jl McClellan; Rt Enos; Ja Carson; R Fayad; M Nagarkatti; Ps Nagarkatti; D Altomare; Ke Creek; Ea Murphy
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

7.  Functions and regulation of MUC13 mucin in colon cancer cells.

Authors:  Brij K Gupta; Diane M Maher; Mara C Ebeling; Phillip D Stephenson; Susan E Puumala; Michael R Koch; Hiroyuki Aburatani; Meena Jaggi; Subhash C Chauhan
Journal:  J Gastroenterol       Date:  2013-10-07       Impact factor: 7.527

8.  Identification of prosaposin and transgelin as potential biomarkers for gallbladder cancer using quantitative proteomics.

Authors:  Nandini A Sahasrabuddhe; Mustafa A Barbhuiya; Shushruta Bhunia; Tejaswini Subbannayya; Harsha Gowda; Jayshree Advani; Braj R Shrivastav; Sanjay Navani; Pamela Leal; Juan Carlos Roa; Raghothama Chaerkady; Sanjeev Gupta; Aditi Chatterjee; Akhilesh Pandey; Pramod K Tiwari
Journal:  Biochem Biophys Res Commun       Date:  2014-03-20       Impact factor: 3.575

Review 9.  Mucins in cancer: function, prognosis and therapy.

Authors:  Donald W Kufe
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

10.  Increased expression and aberrant localization of mucin 13 in metastatic colon cancer.

Authors:  Brij K Gupta; Diane M Maher; Mara C Ebeling; Vasudha Sundram; Michael D Koch; Douglas W Lynch; Teresa Bohlmeyer; Akira Watanabe; Hiroyuki Aburatani; Susan E Puumala; Meena Jaggi; Subhash C Chauhan
Journal:  J Histochem Cytochem       Date:  2012-08-20       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.